Dynavax Technologies (DVAX) Expected to Announce Earnings on Wednesday

Dynavax Technologies (NASDAQ:DVAX) will likely be announcing its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $94.0040 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $95.44 million for the quarter, compared to analyst estimates of $87.55 million. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Trading Down 0.7%

Shares of DVAX opened at $10.19 on Tuesday. Dynavax Technologies has a 52-week low of $9.20 and a 52-week high of $14.63. The business’s fifty day moving average is $10.00 and its 200-day moving average is $10.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -22.15 and a beta of 1.13.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DVAX. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Wall Street Zen upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $24.33.

Insider Buying and Selling

In related news, Director Scott Dunseth Myers bought 3,800 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the acquisition, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. This represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. lifted its stake in shares of Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the period. State of Wyoming acquired a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $304,000. Tower Research Capital LLC TRC lifted its stake in shares of Dynavax Technologies by 319.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 12,371 shares during the period. E Fund Management Co. Ltd. lifted its stake in shares of Dynavax Technologies by 17.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,752 shares during the period. Finally, Man Group plc lifted its stake in shares of Dynavax Technologies by 925.5% in the 2nd quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company’s stock valued at $4,443,000 after purchasing an additional 404,175 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.